Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexicon Pharmaceuticals, Inc. filings document a biopharmaceutical issuer with common stock listed on The Nasdaq Capital Market under LXRX. Its regulatory record includes Form 8-K reports on operating and financial results, clinical and regulatory updates, material agreements, debt financing, equity offerings and conversions of preferred stock into common stock.
Proxy and governance filings describe director elections, executive compensation, equity incentive plans and shareholder voting matters. Registration and prospectus-related disclosures address common-stock issuance programs, capital structure and public-market financing alongside the company's development programs in cardiometabolic and neurologic disease areas.
LEXICON PHARMACEUTICALS, INC. director Judith L. Swain exercised restricted stock units into common shares. She acquired 89,312 shares of common stock at a stated price of $0.00 per share through the conversion of restricted stock units. Following this transaction, she directly holds 174,486 common shares. The restricted stock units represented a contingent right to receive one common share per unit and vested in full on the first anniversary of the grant date.
Lexicon Pharmaceuticals director Diane E. Sullivan reported the vesting and exercise of restricted stock units into common shares. On June 3, 2026, 89,312 restricted stock units converted into 89,312 shares of common stock at a stated price of $0.00 per share, reflecting stock-based compensation rather than a market purchase. Following this transaction, Sullivan directly owned 126,122 shares of common stock. Footnotes explain that each restricted stock unit represented a contingent right to receive one share and that the award vested in full on the first anniversary of its grant date.
LEXICON PHARMACEUTICALS director Christopher J. Sobecki exercised restricted stock units into common shares. He converted 89,312 restricted stock units into 89,312 shares of common stock, consistent with each unit representing one share. Following this stock-based compensation event, he directly holds 293,177 shares of common stock.
Lexicon Pharmaceuticals director Ivan Cheung exercised restricted stock units into common shares. On June 3, 2026, Cheung converted 89,312 restricted stock units into 89,312 shares of common stock at a price of $0.00 per share, a non-cash equity award event.
Following the transaction, Cheung directly holds 89,312 common shares and no restricted stock units remain from this grant. Each restricted stock unit represented a contingent right to receive one share of common stock, vesting in full on the first anniversary of the grant date.
LEXICON PHARMACEUTICALS director Sam L. Barker exercised restricted stock units into common shares. On 2026-06-03, 89,312 restricted stock units converted into 89,312 shares of common stock at a stated price of $0.00 per share, reflecting equity compensation rather than an open‑market trade.
Following this conversion, Barker directly owns 213,771 shares of common stock. The footnotes explain that each restricted stock unit represented a contingent right to receive one share of common stock, and that the award vested in full on the first anniversary of its grant date.
LEXICON PHARMACEUTICALS, INC. director Philippe Amouyal exercised restricted stock units into common shares. On June 3, 2026, he converted 89,312 restricted stock units into the same number of common shares at a stated price of $0.00 per share, reflecting a compensation-related vesting rather than a market purchase or sale. After the transaction, he held 374,486 common shares directly. The derivative position in these restricted stock units was fully settled, leaving no remaining units from this grant.
LEXICON PHARMACEUTICALS, INC. director Raymond Debbane exercised restricted stock units into common stock. He converted 89,312 restricted stock units at an exercise price of $0.00 per unit into 89,312 shares of common stock and now holds 1,995,498 shares directly. Entities associated with him hold additional indirect positions of 35,402,689, 5,451,204, 7,362,368 and 1,538,462 common shares as of the reported date.
LEXICON PHARMACEUTICALS, INC. (LXRX) insider group led by Artal entities reported an internal restructuring of their stake. Artal Participations S.a r.l. had previously acquired 408,434.70 shares of Series B convertible preferred stock at $65.00 per share. Each preferred share automatically converted into 50 shares of common stock once shareholder approval and other conditions were satisfied, which occurred on April 30, 2026. As a result, 408,434.70 preferred shares converted into 20,421,735 shares of common stock. Following the conversion, Artal Participations S.a r.l. indirectly holds 175,156,062 shares of common stock, reflecting a large, ongoing position rather than an open-market purchase or sale.
Artal Participations and related investment entities update their Schedule 13D on Lexicon Pharmaceuticals to reflect additional preferred share purchases and conversion into common stock. On February 17, 2026, Artal Participations S.a r.l. bought 41,289.58 shares of Preferred Stock at $65.00 per share under a Preferred Purchase Agreement.
Together with earlier purchases, 408,434.70 preferred shares automatically converted on April 30, 2026 into 20,421,735 shares of Lexicon common stock after charter approval conditions were met. The reporting persons collectively beneficially own 227,034,705 Lexicon common shares, or 51.1% of the 444,196,390 shares outstanding as of May 4, 2026, giving the group majority beneficial ownership.
Lexicon Pharmaceuticals reported sharply improved Q1 2026 results. Revenue rose to $21.1 million from $1.3 million, driven mainly by $20.0 million of development milestone revenue from its Novo Nordisk licensing agreement, alongside modest INPEFA net product sales of $1.1 million.
Net loss narrowed to $1.0 million, or less than $0.01 per share, compared with a $25.3 million loss a year earlier, as both research and development and selling, general and administrative expenses declined. Operating cash outflow was $14.7 million, but total cash, cash equivalents, short‑term investments and restricted cash increased to $199.7 million as of March 31, 2026, helped by approximately $96.5 million of February common and preferred stock issuances.
The company highlighted progress across its pipeline, including the SONATA‑HCM Phase 3 trial of sotagliflozin, ongoing efforts to potentially resubmit the ZYNQUISTA NDA for type 1 diabetes, Fast Track‑designated pilavapadin in diabetic peripheral neuropathic pain, and Novo Nordisk’s Phase 1 work on LX9851. Management believes current liquidity, collaborations and a new $100 million Hercules loan facility support operations for at least the next 12 months.